Company Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis.
It has a collaboration with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.
Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | Steven Nichtberger |
Contact Details
Address: 2929 Arch Street, Suite 600 Philadelphia, Pennsylvania 19104 United States | |
| Phone | 267 759 3100 |
| Website | cabalettabio.com |
Stock Details
| Ticker Symbol | CABA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001759138 |
| CUSIP Number | 12674W109 |
| ISIN Number | US12674W1099 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven A. Nichtberger M.D. | Co-Founder, Chairman, Chief Executive Officer and President |
| Dr. David J. Chang FACR, M.D., M.P.H. | Chief Medical Officer |
| Dr. Gwendolyn K. Binder Ph.D. | President of Science and Technology |
| Dr. Michael C. Milone M.D., Ph.D. | Co-Founder and Co-Chair of Scientific Advisory Board |
| Dr. Aimee Payne M.D., Ph.D. | Co-Founder and Co-Chair of Scientific Advisory Board |
| Anup Marda M.B.A. | Chief Financial Officer |
| Dr. Qing Sarah Yuan Ph.D. | Chief Technology Officer |
| Dr. Samik Basu M.D. | Chief Scientific Officer |
| Michael Gerard J.D. | General Counsel and Secretary |
| Heather Harte-Hall M.Sc. | Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2025 | SCHEDULE 13G | Filing |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 424B5 | Filing |
| Jun 11, 2025 | 424B5 | Filing |
| Jun 11, 2025 | 8-K | Current Report |
| Jun 10, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 13, 2025 | ARS | Filing |